85-2069-91　SP-2509 1mg　CAS No:1423715-09-6　215891

特徴

• LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation isfrequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNAknockdown of LSD1 has been shown to suppress growth of cancer cells. SP2509 is a selectiveand reversible LSD1 inhibitor with an IC50 of 10nM. SP2509 demonstrates a high specificity forLSD1, with no effect on MAOi.
• Synonyms:(E)-N'-(1-(5-chloro-2- hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, SP-2509
• Molecular Weight:437.9
• Molecular Formula:C19H20ClN3O5S
• Appearance:Supplied as a solid.
• Purity:≥95% (HPLC)
• Solubility:DMSO
• Storage and Stability:Store and 4°C for short term, -20°C for long term storage. Stable for at least 2 years after receipt when stored at -20°C.

仕様

• Size：1mg
• Grade：Highly Purified
• Purity：≥95% (HPLC)
• Form：Supplied as a solid.
• Molecular Formula：C19H20ClN3O5S
• Molecular Weight Non Ab：437.9
• EU Commodity Code：38220090
• この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
• 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
• CAS No ：1423715-09-6

• 【試薬に関するお問合せ】
• アズワン株式会社 試薬・プロセス材料グループ
• TEL：06-6447-8641
• FAX：06-6447-8642
• E-mail：[email protected]